Brokerages predict that Marrone Bio Innovations Inc (NASDAQ:MBII) will announce earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Marrone Bio Innovations’ earnings. Marrone Bio Innovations posted earnings per share of ($0.38) in the same quarter last year, which suggests a positive year over year growth rate of 18.4%. The business is expected to announce its next quarterly earnings results on Thursday, May 11th.
On average, analysts expect that Marrone Bio Innovations will report full-year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.41). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.61) per share, with EPS estimates ranging from ($1.05) to ($0.25). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings results on Wednesday, March 29th. The basic materials company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.06. The business had revenue of $2.69 million for the quarter.
Separately, Zacks Investment Research raised shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Wednesday, January 18th.
An institutional investor recently bought a new position in Marrone Bio Innovations stock. Ardsley Advisory Partners acquired a new position in shares of Marrone Bio Innovations Inc (NASDAQ:MBII) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 774,438 shares of the basic materials company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned approximately 3.15% of Marrone Bio Innovations at the end of the most recent reporting period. 37.95% of the stock is currently owned by institutional investors and hedge funds.
Marrone Bio Innovations (NASDAQ:MBII) traded down 1.12% during midday trading on Tuesday, hitting $1.77. 31,433 shares of the stock traded hands. Marrone Bio Innovations has a 52 week low of $0.60 and a 52 week high of $2.79. The company’s market capitalization is $43.84 million. The stock’s 50-day moving average price is $1.92 and its 200 day moving average price is $2.07.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marrone Bio Innovations Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc and related companies with MarketBeat.com's FREE daily email newsletter.